Cerebral perfusion pressure (CPP) is a critical value for determining neurological health and determining the effects of treatments used to treat increased ICP (Intracranial Pressure). It is the pressure gradient between the Arterial and Venous systems in the brain, and is generally maintained between 60 and 130 mmHg. In most cases, CPP is calculated using the MAP (mean arterial pressure) minus the ICP (intracranial pressure). However, other factors such as intracranial blood volume, intracranial compliance, and ventricular compliance can also affect CPP. Normal CPP helps to meet the brain’s metabolic needs by guaranteeing that the brain has enough oxygen, glucose, and other nutrients to function properly. If the CPP rises above or falls below the normal range, the brain cannot receive an adequate supply of these nutrients and may cause severe neurological damage. CPP can be increased by increasing MAP or decreasing ICP, which can be achieved by different interventions. These include using medications to reduce ICP, applying an external pressure to the head, or using a shunt system to drain out excess CSF (cerebral spinal fluid). CPP can also be lowered by increasing ICP further or decreasing MAP, which can be done surgically. In certain severe cases, a decrease in CPP can be fatal. However, an increase in CPP can be beneficial in reducing the risk of ischemia, increasing oxygen delivery, preventing hypoxia, and reducing intracranial edema. It is important to monitor CPP in order to provide the best care to a patient. CPP measurement can be done using invasive or non-invasive methods. Invasive methods include measuring around an invasive arterial catheter or ventricular catheter, while non-invasive methods can be done using cerebral autoregulation or ultrasound technology.
Title : Scalp acupuncture with functional electrical stimulation for the treatment children with autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy, Australia
Title : A structure-based strategy to target pathogenic α-synuclein in Parkinson’s disease
Salvador Ventura, Autonomous University of Barcelona, Spain
Title : Rabies: Challenges in taming the beast
Alan C Jackson, University of Calgary, Canada
Title : Designing and managing intelligent and ethical transformed health and social care ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Understanding Alzheimer's disease biomarkers across diverse populations - Opportunities and Insights for novel prevision medicine approaches
Sid O Bryant, Texas College of Osteopathic Medicine and University of North Texas Health Science Center Fort Worth, United States